Drug Approval | October 20, 2023
USFDA approves Pfizer’s Velsipity for adults with Ulcerative Colitis
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Prateek has more than 23 years of rich experience in Human Resource
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Subscribe To Our Newsletter & Stay Updated
